Carl Zeiss Meditec AG (OTCMKTS:CZMWY) Receives Average Rating of “Reduce” from Brokerages

Carl Zeiss Meditec AG (OTCMKTS:CZMWY) has received a consensus rating of “Reduce” from the six brokerages that are covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company.

A number of research analysts recently issued reports on CZMWY shares. UBS Group downgraded Carl Zeiss Meditec from a “neutral” rating to a “sell” rating in a research note on Tuesday, August 11th. Zacks Research downgraded Carl Zeiss Meditec from a “hold” rating to a “strong sell” rating in a report on Tuesday, August 11th. Finally, Morgan Stanley started coverage on shares of Carl Zeiss Meditec in a research report on Wednesday. They set an “underweight” rating on the stock.

Carl Zeiss Meditec Price Performance

Carl Zeiss Meditec stock opened at $36.61 on Friday. Carl Zeiss Meditec has a fifty-two week low of $26.65 and a fifty-two week high of $55.94. The stock has a 50-day simple moving average of $34.59 and a 200-day simple moving average of $31.59.

About Carl Zeiss Meditec

Carl Zeiss Meditec AG is a global medical technology company headquartered in Jena, Germany. Founded in 2002 as a spin-off from the Carl Zeiss Group, the business leverages the parent company’s expertise in optics and precision engineering. Over the years, Carl Zeiss Meditec has grown through organic development and strategic acquisitions, becoming a recognized provider of innovative surgical and diagnostic solutions for eye care and microsurgery.

The company’s core offerings span two primary divisions: Ophthalmic Devices and Microsurgery.